Sector
Healthcare
Industry
Biotechnology
Employees
114
First IPO Date
March 30, 2017
| Name | Title | Pay | Year Born |
| Andrew Obenshain | Chief Executive Officer | 152,244 | 1974 |
| Martine Zimmermann | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | 226,090 | 1969 |
| Jason A. Campagna | President of Research and Development & Chief Medical Officer | 338,177 | 1966 |
| Jean Volatier | Executive VP Finance & Corporate Social Responsibility | 355,566 | 1965 |
| Pierre Broqua | Co-Founder | 411,801 | 1962 |
| Axel-Sven Malkomes | Chief Financial Officer | 0 | 1967 |
| Nathalie Harroy | Head of Human Resources | 0 | 1967 |
| Nazira Amra | Chief Commercial Strategy Officer | 0 | N/A |
| Susan Coles | Chief Legal Officer | 0 | 1966 |
| Eric Duranson | General Counsel | 0 | 1974 |
| Pamela Herbster | Chief People Officer | 0 | N/A |
| Pascaline Clerc | Executive Vice President of External and Corporate Affairs | 0 | 1980 |
Inventiva S.A. is a clinical-stage biopharmaceutical firm dedicated to developing oral small molecule therapies. Its primary therapeutic focus areas include non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other conditions. The company's lead investigational compound, Lanifibranor, has successfully completed its Phase IIb clinical trial for NASH treatment. Additionally, Inventiva is advancing Odiparcil, which has finished a Phase IIa clinical study for the management of MPS VI subtype disease. The organization also maintains a portfolio of earlier-stage programs targeting oncology and other illnesses. Inventiva S.A. has established strategic collaborations, including one with AbbVie for autoimmune disease treatments and another with Boehringer Ingelheim International GmbH for developing novel therapies for idiopathic pulmonary fibrosis. Founded in 2011, the company is based in Daix, France.